Skip to main navigation
Skip to search
Skip to main content
University of Luebeck Home
English
Deutsch
Home
Research Units
Experts
Publications
Projects
Datasets
Prizes
Spin-Offs
Activities
Media
Search by expertise, name or affiliation
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
RUBY Investigators
Clinic of Gynecology and Obstetrics
Charles University
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
100%
Endometrium Cancer
100%
Progression Free Survival
50%
Paclitaxel
25%
Carboplatin
25%
Overall Survival
25%
Immune Checkpoint Inhibitor
12%
Neoplasm
12%
Solid Malignant Neoplasm
12%
Programmed Death 1 Receptor
12%
Nausea
12%